摘要
目的:探讨乙肝患者血清中e抗原(HBeAg)与乙肝病毒DNA(HBV-DNA)之间的关系。方法:选取305例HBsAg阳性的乙肝患者血清标本,分别用微粒子酶免疫分析法(MEIA)和核酸扩增荧光定量法(FQ-PCR)检测HBeAg和HBV-DNA。结果:305例标本中,HBeAg阳性率为71.48%,而HBV-DNA阳性率为58.69%。HBeAg阳性标本中,HBV-DNA阳性率为66.05%;而HBeAg阴性标本中,HBV-DNA阳性率为40.23%,两者有显著性差异(χ2=17.11,P<0.01)。不同浓度组HBeAg和HBV-DNA检测结果比较,有统计学意义(χ2=35.67,P<0.01)。结论:HBV-DNA比HBeAg能更准确反映出乙肝病毒复制情况,可以更好地指导临床进行乙肝治疗。
Objective:To explore the relationship between serum HBeAg and HBV-DNA contents. Methods:305 serum samples which have shown HBsAg positive were included.HBeAg was tested by microparticle enzyme immunoassays (MEIA)and HBV-DNA was tested by fluorescence quantitative polymerase chain reaction (FQ-PCR). Results: 71.48% of 305 samples showed HBeAg positive, while 58.69% samples showed HBV-DNA positive.In the HBeAg positive samples, the positive percentage of HBV-DNA was 66.05%,and in the HBeAg negative samples,the positive percentage of HBV-DNA was 40.23%,which showed there was significant difference(Х^2=17.11 ,P〈0.01)between HBeAg and HBV-DNA.The differences between HBeAg in a series of concentration and the test results of HBV-DNA were also significant(Х^2=35.67 ,P〈 0.01 ). Conclusion: Compared with HBeAg,HBV-DNA is a better maker for detecting the replication of HBV (hepatitis B virus),which would be helpful for the HBV clinical therapy.
出处
《中国医药导报》
CAS
2009年第5期50-51,共2页
China Medical Herald